Form 4: Notable Labs CEO Thomas Bock Receives Stock and Options Grant

Thomas Bock, CEO of Notable Labs, receives 400,000 ordinary shares and options for 150,000 shares.

Summary

• Thomas Bock, the CEO of Notable Labs, Ltd., received 400,000 ordinary shares on May 8, 2024.
• These shares were granted at a price of $0.
• The shares vest in four equal annual installments from the date of grant.
• Bock also received stock options for 150,000 ordinary shares with an exercise price of $1.19.
• These options also vest in equal annual installments over a two-year period from the date of grant and expire on May 8, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The vesting schedules suggest a long-term commitment.

Positives

• The grant of shares and options to the CEO aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the CEO.

Industry Context

Stock and option grants are a common form of executive compensation in the biotech industry, aligning management incentives with company performance and shareholder value.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry typically include a mix of salary, stock options, and restricted stock units.
• The vesting schedules for these grants are often tied to performance milestones or continued employment.
• Comparing the size and terms of this grant to those of CEOs at similarly sized biotech companies would provide a better understanding of its competitiveness.

Stakeholder Impact

• Shareholders may view the grant positively as it incentivizes the CEO to increase company value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, ordinary shares, Thomas Bock, Notable Labs, CEO, Form 4, grant, vesting